We recently demonstrated that the anticancer human mTORinhibitorsapanisertib displays antimalarial activity in a malaria mouse modelof infection and inhibits multiple Plasmodium kinases,including the high-value targets phosphatidylinositol 4-kinase typeIII beta (PI4Kβ) and cGMP-dependent protein kinase (PKG). Here, PRKG1 is linked to malaria.